Amgen sees off Sanofi and J&J to clinch the rare disease player for $28bn, ensuring that the M&A year ends with a bang.
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.